Which has stronger valuation & earnings, VINC or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is VINC or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Ampio Pharmaceuticals N/A N/A N/A

Is PTPI or VINC more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Vincerx Pharma N/A -248.33% -132.73%

Which has better valuation and earnings, ARDS or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00 Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is ARDS or VINC more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Do analysts rate ADTX or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, ADTX or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt N/A N/A -$41.71M -$100.79 thousand N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is ADTX or VINC more profitable?

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Vincerx Pharma N/A -248.33% -132.73%

Which has preferable earnings and valuation, VINC or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is VINC or SCPS more profitable?

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Scopus BioPharma N/A N/A N/A

Vincerx Pharma (VINC) Competitors

$0.01 0.00 (-3.94%)

As of 09:30 AM Eastern

Compare

VINC vs. AMPE, PTPI, ARDS, ADTX, and SCPS

Should you buy Vincerx Pharma stock or one of its competitors? MarketBeat compares Vincerx Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vincerx Pharma include Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Aridis Pharmaceuticals (ARDS), Aditxt (ADTX), and Scopus BioPharma (SCPS). These companies are all part of the "pharmaceutical products" industry.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Vincerx Pharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Ampio Pharmaceuticals	Neutral

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Ampio Pharmaceuticals	N/A	N/A	N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Summary

Vincerx Pharma and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Vincerx Pharma	N/A	-248.33%	-132.73%

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Petros Pharmaceuticals has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

In the previous week, Petros Pharmaceuticals had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for Vincerx Pharma. Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 7 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Aridis Pharmaceuticals has a beta of 49.37, suggesting that its stock price is 4,837% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Vincerx Pharma on 6 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aditxt had 3 more articles in the media than Vincerx Pharma. MarketBeat recorded 3 mentions for Aditxt and 0 mentions for Vincerx Pharma. Aditxt's average media sentiment score of 0.47 beat Vincerx Pharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Vincerx Pharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Vincerx Pharma	N/A	-248.33%	-132.73%

Aditxt has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Summary

Vincerx Pharma beats Aditxt on 7 of the 12 factors compared between the two stocks.

How does Vincerx Pharma compare to Scopus BioPharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

44.0% of Vincerx Pharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

In the previous week, Scopus BioPharma had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Scopus BioPharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Scopus BioPharma	N/A	N/A	N/A

Summary

Scopus BioPharma beats Vincerx Pharma on 4 of the 7 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VINC vs. The Competition

Export

Metric	Vincerx Pharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64K	$998.86M	$6.30B	$12.43B
Dividend Yield	N/A	4.84%	2.69%	5.33%
P/E Ratio	0.00	1.49	24.03	24.35
Price / Sales	N/A	122.18	518.85	115.59
Price / Cash	N/A	20.06	41.39	55.53
Price / Book	0.00	8.12	9.98	6.72
Net Income	-$40.16M	-$3.91M	$3.56B	$337.03M
7 Day Performance	N/A	-1.73%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	N/A	111.96%	28.76%	33.98%

Vincerx Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VINC Vincerx Pharma	N/A	$0.01 -3.9%	N/A	-74.1%	$64K	N/A	N/A	60	Gap Down
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.01 flat	N/A	-81.6%	$190K	$5.11M	N/A	20	Gap Up
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+100.0%	$91K	N/A	0.02	30	Gap Up
ADTX Aditxt	1.3003 of 5 stars	$0.25 -50.6%	N/A	-100.0%	$17K	$14.34K	N/A	60	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vincerx Pharma (VINC) Competitors

VINC vs. AMPE, PTPI, ARDS, ADTX, and SCPS

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Aditxt?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vincerx Pharma (VINC) Competitors

VINC vs. AMPE, PTPI, ARDS, ADTX, and SCPS

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Which has more risk & volatility, VINC or AMPE?

Does the media favor VINC or AMPE?

Do institutionals and insiders believe in VINC or AMPE?

Is VINC or AMPE more profitable?

Which has stronger valuation & earnings, VINC or AMPE?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Which has better valuation and earnings, PTPI or VINC?

Is PTPI or VINC more profitable?

Do institutionals and insiders hold more shares of PTPI or VINC?

Which has more risk & volatility, PTPI or VINC?

Does the media prefer PTPI or VINC?

Summary

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Which has more risk & volatility, ARDS or VINC?

Is ARDS or VINC more profitable?

Which has better valuation and earnings, ARDS or VINC?

Does the media prefer ARDS or VINC?

Do institutionals and insiders hold more shares of ARDS or VINC?

Summary

How does Vincerx Pharma compare to Aditxt?

Do institutionals and insiders hold more shares of ADTX or VINC?

Does the media prefer ADTX or VINC?

Do analysts rate ADTX or VINC?

Which has stronger valuation & earnings, ADTX or VINC?

Is ADTX or VINC more profitable?

Which has more volatility and risk, ADTX or VINC?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Do insiders and institutionals believe in VINC or SCPS?

Which has more volatility & risk, VINC or SCPS?

Does the media prefer VINC or SCPS?

Which has preferable earnings and valuation, VINC or SCPS?

Is VINC or SCPS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools